Stock A003000 BUKWANG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Bukwang Pharmaceutical Co., Ltd.

Equities

A003000

KR7003000007

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 24/05/2024 am IST 		5-day change 1st Jan Change
5,900 KRW -1.67% Intraday chart for Bukwang Pharmaceutical Co., Ltd. -9.92% -3.28%
14/05 Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
01/04 H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
H Delta Private Equity Partnership completed the acquisition of 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.
CI
Bukwang Pharmaceutical Shares Surge Following Buyback Program Announcement
MT
H Delta Private Equity Partnership agreed to acquire 24.4% stake in Contera Pharma ApS from Bukwang Pharmaceutical Co., Ltd. for KRW 6.3 billion.
CI
Bukwang Pharmaceutical : IR Fact Book 4Q23 (Reviewed by External Auditor)
PU
Bukwang Pharmaceutical : IR presentation 4Q23 (Reviewed by External Auditor)
PU
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
Bukwang Pharmaceutical Co., Ltd.(KOSE:A003000) dropped from KOSPI 200 Index
CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
OCI Company Ltd. completed the acquisition of additional 10.878134% stake in Bukwang Pharmaceutical Co., Ltd. (KOSE : A003000) from Kim Sanghun and 8 other shareholders for approximately KRW 150 billion.
CI
OCI Company Ltd. agreed to acquire an additional 10.878134% stake in Bukwang Pharmaceutical Co., Ltd. (KOSE : A003000) from Kim Sanghun and 8 other shareholders for approximately KRW 150 billion.
CI
ImmPACT Bio USA Inc. announced that it has received $110.855843 million in funding from a group of investors
CI
ImmPACT Bio USA Inc. announced that it expects to receive $110.855843 million in funding
CI
Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A003000 Stock
  4. News Bukwang Pharmaceutical Co., Ltd.